Literature DB >> 17285366

Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.

Lisa M Neff1, Michelle Weil, Alan Cole, Thomas R Hedges, William Shucart, Donald Lawrence, Jay-Jiguang Zhu, Arthur S Tischler, Ronald M Lechan.   

Abstract

Prolactinomas are common tumors of the anterior pituitary gland. While conventional therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are usually effective in controlling tumor growth, some patients develop treatment-resistant tumors. In this report, we describe a patient with an invasive prolactinoma resistant to conventional therapy that responded to the administration of the alkylating agent, temozolomide.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17285366     DOI： 10.1007/s11102-007-0014-1

Source DB:  PubMed          Journal:  Pituitary        ISSN： 1386-341X            Impact factor:   4.107


  35 in total

Review 1.  Medical management of prolactin-secreting pituitary adenomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

2.  Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.

Authors:  W P Roos; L F Z Batista; S C Naumann; W Wick; M Weller; C F M Menck; B Kaina
Journal:  Oncogene       Date:  2006-07-03       Impact factor: 9.867

Review 3.  Prolactinomas and pregnancy.

Authors:  Marcello Delano Bronstein
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

4.  Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.

Authors:  I Shimon; X Yan; J E Taylor; M H Weiss; M D Culler; S Melmed
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

5.  Cortistatin-17 and somatostatin-14 display the same effects on growth hormone, prolactin, and insulin secretion in patients with acromegaly or prolactinoma.

Authors:  S Grottoli; V Gasco; F Broglio; R Baldelli; F Ragazzoni; F Gallenca; A Mainolfi; F Prodam; G Muccioli; E Ghigo
Journal:  J Clin Endocrinol Metab       Date:  2006-01-31       Impact factor: 5.958

6.  Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas.

Authors:  P Jaquet; L Ouafik; A Saveanu; G Gunz; F Fina; H Dufour; M D Culler; J P Moreau; A Enjalbert
Journal:  J Clin Endocrinol Metab       Date:  1999-09       Impact factor: 5.958

7.  Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells.

Authors:  S W Lamberts; T Verleun; L Hofland; R Oosterom
Journal:  J Clin Endocrinol Metab       Date:  1986-12       Impact factor: 5.958

8.  The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.

Authors:  Mary P Gillam; Stewart Middler; Daniel J Freed; Mark E Molitch
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

9.  Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas.

Authors:  S W Lamberts; T Verleun; R Oosterom
Journal:  Neuroendocrinology       Date:  1982       Impact factor: 4.914

10.  The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.

Authors:  S W Lamberts; M Zweens; J G Klijn; C C van Vroonhoven; S Z Stefanko; E Del Pozo
Journal:  Clin Endocrinol (Oxf)       Date:  1986-08       Impact factor: 3.478
View more
  21 in total

Review 1.  Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.

Authors:  A K Annamalai; A F Dean; N Kandasamy; K Kovacs; H Burton; D J Halsall; A S Shaw; N M Antoun; H K Cheow; R W Kirollos; J D Pickard; H L Simpson; S J Jefferies; N G Burnet; M Gurnell
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

2.  Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.

Authors:  Troy H Dillard; S Humayun Gultekin; Johnny B Delashaw; Chris G Yedinak; Edward A Neuwelt; Maria Fleseriu
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

3.  Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands.

Authors:  George Vlotides; Emily Siegel; Ines Donangelo; Shiri Gutman; Song-Guang Ren; Shlomo Melmed
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 4.  Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.

Authors:  Akira Matsuno; Mineko Murakami; Katsumi Hoya; Shoko M Yamada; Shinya Miyamoto; So Yamada; Jae-Hyun Son; Hajime Nishido; Fuyuaki Ide; Hiroshi Nagashima; Mutsumi Sugaya; Toshio Hirohata; Akiko Mizutani; Hiroko Okinaga; Yudo Ishii; Shigeyuki Tahara; Akira Teramoto; R Yoshiyuki Osamura
Journal:  Med Mol Morphol       Date:  2013-08-17       Impact factor: 2.309

5.  Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports.

Authors:  Yan Ji; Rachel Isaksson Vogel; Emil Lou
Journal:  Neurooncol Pract       Date:  2015-11-12

6.  Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly.

Authors:  Emilie Morin; France Berthelet; John Weisnagel; Martin Bidlingmaier; Omar Serri
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

Review 7.  Management of aggressive pituitary adenomas and pituitary carcinomas.

Authors:  Anthony Heaney
Journal:  J Neurooncol       Date:  2014-03-02       Impact factor: 4.130

8.  Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.

Authors:  Marie S Thearle; Pamela U Freda; Jeffrey N Bruce; Steven R Isaacson; Yoomi Lee; Robert L Fine
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107

9.  Heregulin regulates prolactinoma gene expression.

Authors:  George Vlotides; Odelia Cooper; Yen-Hao Chen; Song-Guang Ren; Yona Greenman; Shlomo Melmed
Journal:  Cancer Res       Date:  2009-04-28       Impact factor: 12.701

Review 10.  MGMT immunoexpression in aggressive pituitary adenoma and carcinoma.

Authors:  Queenie Lau; Bernd Scheithauer; Kalman Kovacs; Eva Horvath; Luis V Syro; Ricardo Lloyd
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.